EGFR and non-small cell lung carcinoma: The introduction of epidermal growth factor receptor (EGFR) gene tyrosine kinase inhibitors (TKIs) in chemonaive patients with advanced non-small cell lung cancer (NSCLC) has dramatically improved the progression-free survival compared to standard chemotherapy.